LY96 and Sepsis: Failure in the recent clinical trial of TAK-242, a small molecule inhibitor of TLR4, and that of eritoran, a specific antagonist of MD2-TLR4, for patients with severe sepsis have cast a shadow on the idea to target TLR4 to develop novel therapeutic interventions for sepsis.